The need for predictive, prognostic, objective and complementary blood-based biomarkers in osteoarthritis (OA)

Bay-Jensen, Anne-Christine; Henrotin, Yves; Karsdal, Morten; Mobasheri, Ali

doi:10.1016/j.ebiom.2016.05.004

Download

Article (Scientific journals)

The need for predictive, prognostic, objective and complementary blood-based biomarkers in osteoarthritis (OA)

Bay-Jensen, Anne-Christine; Henrotin, Yves; Karsdal, Morten et al.

2016 • In EBioMedicine

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/197475

DOI
10.1016/j.ebiom.2016.05.004

PubMed
27322444

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

eBioMedicine2016 AC Bay-Jensen, Henrotin.pdf

Publisher postprint (378.99 kB)

Download

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Disciplines :

Rheumatology

Author, co-author :

Bay-Jensen, Anne-Christine

Henrotin, Yves ; Université de Liège > Département des sciences de la motricité > Unité de recherche sur l'os et le cartilage (U.R.O.C.)

Karsdal, Morten

Mobasheri, Ali

Language :

English

Title :

The need for predictive, prognostic, objective and complementary blood-based biomarkers in osteoarthritis (OA)

Publication date :

2016

Journal title :

EBioMedicine

eISSN :

2352-3964

Publisher :

Elsevier, Amsterdam, Netherlands

Peer reviewed :

Peer Reviewed verified by ORBi

European Projects :

FP7 - 305815 - D-BOARD - Novel Diagnostics and Biomarkers for Early Identification of Chronic Inflammatory Joint Diseases

Funders :

CE - Commission Européenne [BE]

Available on ORBi :

since 27 May 2016

Statistics

Number of views

44 (6 by ULiège)

Number of downloads

225 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Bauer D.C., Hunter D.J., Abramson S.B., Attur M., Corr M., Felson D., Heinegård D., Jordan J.M., Kepler T.B., Lane N.E., et al. Classification of osteoarthritis biomarkers: a proposed approach. Osteoarthr. Cartil. 2006, 14:723-727.
Bay-Jensen A.C., Reker D., Kjelgaard-Petersen C.F., Mobasheri A., Karsdal M.A., Ladel C., Henrotin Y., Thudium C.S. Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthr. Cartil. 2016, 24:9-20.
Conaghan P.G. Osteoarthritis in 2012: parallel evolution of OA phenotypes and therapies. Nat. Rev. Rheumatol. 2013, 9:68-70.
Bay-Jensen A.C.C., Reker D., Kjelgaard-Petersen C.F.F., Mobasheri A., Karsdal M.A.A., Ladel C., Henrotin Y., Thudium C.S.S. Osteoarthritis year in review 2015: soluble biomarkers and the BIPED criteria. Osteoarthr. Cartil. 2016, 24:9-20. 10.1016/j.joca.2015.10.014.
Karsdal M.A., Christiansen C., Ladel C., Henriksen K., VB K., AC B.-J. Osteoarthritis - a case for personalized health care?. Osteoarthr. Cartil. 2013.
Kraus V.B., Blanco F.J., Englund M., Karsdal M.A., Lohmander L.S. Call for standardized definitions of osteoarthritis and risk stratification for clinical trials and clinical use. Osteoarthr. Cartil. 2015.
Kraus V.B., Burnett B., Coindreau J., Cottrell S., Eyre D., Gendreau M., Gardiner J., Garnero P., Hardin J., Henrotin Y., et al. Application of biomarkers in the development of drugs intended for the treatment of osteoarthritis. Osteoarthr. Cartil. 2011, 19:515-542.
Mobasheri A. The future of osteoarthritis therapeutics: targeted pharmacological therapy. Curr. Rheumatol. Rep. 2013, 15:364.
Patterson S.D., Cohen N., Karnoub M., Truter S.L., Emison E., Khambata-Ford S., Spear B., Ibia E., Sproule R., Barnes D., et al. Prospective-retrospective biomarker analysis for regulatory consideration: white paper from the industry pharmacogenomics working group. Pharmacogenomics 2011, 12:939-951.
Qvist P., Bay-Jensen A.C., Christiansen C., Dam E.B., Pastoureau P., Karsdal M.A. The disease modifying osteoarthritis drug (DMOAD): is it in the horizon?. Pharmacol. Res. 2008, 58:1-7.